MaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed at Improving Patients’ Responses to Immunotherapies
01 11월 2023 - 2:00AM
Business Wire
- Presentation of AI-based screening strategy developed to
identify a new generation of drug candidates, MaaT034 being the
first product from the new range.
- First-time presentation of in vitro data for MaaT034, a new
generation product, demonstrating biological activity that enhanced
responses to Immune Checkpoint Inhibitors (ICIs) therapies.
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a
clinical-stage biotechnology company and a leader in the
development of Microbiome Ecosystem TherapiesTM (MET) dedicated to
enhancing survival for patients with cancer, announced today
the details of two poster presentations at the 38th Society for
Immunotherapy of Cancer (SITC) Annual Meeting, the world-leading
event in immunotherapy, scheduled to be held from November 1-5,
2023, in San Diego, California, U.S.A. Presentations will include
in vitro results for its new Artificial Intelligence (AI)-generated
lead product, MaaT034, designed to improve responses to
immunotherapy for patients with solid tumors. MaaT034 is the first
member of the MET-C platform that can co-cultivate a healthy
microbiota ecosystem. The first-in-human testing is planned for
2025, with the first clinical batches to be produced in 2024.
Nathalie Corvaia, Chief Scientific Officer, states “we
are very excited to present our first pre-clinical data at SITC
showing biological activity for MaaT034, our new generation of
co-cultured products and the robustness of our proprietary
AI-engine, gutPrint®. MaaT034 is active in restoring the integrity
of the gut barrier and stimulating immune cells leading to an
improvement in the immune cell response to ICI therapy. This
bolsters our confidence in our immuno-oncology approach driven by
our AI engine. We are looking forward to moving to clinical
evaluation in 2025.”
Poster Presentation Details:
Poster 1 Title: Evaluation of a new co-cultured microbiome
ecosystem therapy candidate (MaaT03X) for clinical testing as
adjuvant/neoadjuvant to immune checkpoint inhibitors in solid
tumors
Poster Number: 1321
Date & Location: November 3, 2023 – Exhibit Halls A &
B1
Key findings for MaaT034:
- replicates, at large industrial scale, the richness and
diversity of healthy native-based microbiome ecosystems
- restores the integrity of a damaged gut barrier
- activates AhR1 pathway involved in gut homeostasis
- stimulates both myeloid and lymphoid immune cells
- improves immune cell response to ICI therapy
Poster 2 Title: Robust Machine Learning (ML) approach for
screening Microbiome Ecosystem Therapies (MET) drug candidates in
combination with Immune Checkpoint Inhibitors
Poster Number: 1304
Date & Location: November 3, 2023 – Exhibit Halls A &
B1
Key findings for gutPrint® AI engine:
- selection and training of models to grade samples as
“Responder-like” according to the baseline stool metagenomics of
ICI treated cancer patients
- improvement of predictive performance compared to literature
with more patient data, cross studies and indication
- application of the best performing model (mean LODO AUC = 0.65)
to MaaT Pharma’s healthy donor cohort or pooled samples (mixes of
stools from 4 to 8 healthy donors) classified a large majority of
those as “Responder-like” microbiota (especially pooled
samples)
About MaaT Pharma
MaaT Pharma, a clinical-stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma has launched, in
March 2022, an open-label, single-arm Phase 3 clinical trial in
patients with acute GvHD, following the achievement of its proof of
concept in a Phase 2 trial. Its powerful discovery and analysis
platform, gutPrint®, enables the identification of novel disease
targets, evaluation of drug candidates, and identification of
biomarkers for microbiome-related conditions. The company’s
Microbiome Ecosystem Therapies are produced through a standardized
cGMP manufacturing and quality control process to safely deliver
the full diversity of the microbiome in liquid and oral
formulations. MaaT Pharma benefits from the commitment of
world-leading scientists and established relationships with
regulators to support the integration of the use of microbiome
therapies in clinical practice. MaaT Pharma is listed on Euronext
Paris (ticker: MAAT).
Forward-looking Statements
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
1 AhR: Aryl Hydrocarbon Receptor
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231031842923/en/
MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D.
Head of Investor Relations +33 6 16 48 92 50
invest@maat-pharma.com
MaaT Pharma – Media Relations Pauline RICHAUD Senior PR
& Corporate Communications Manager +33 6 14 06 45 92
media@maat-pharma.com
Trophic Communications – Corporate Communications Jacob
VERGHESE or Priscillia PERRIN +49 151 7441 6179 maat@trophic.eu
Maat Pharma (EU:MAAT)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Maat Pharma (EU:MAAT)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024